Tel.:
+34 91 736 2385
LOCAL TIME
Contact:
Katarina Gluic
Hours:
Mon-Thu 8:30-17:00 Fri 8:30-15:00
09:06
For help with a poster, please specify the poster number, the first author and the congress and we will reply shortly.
Poster no.
Contact name
E-mail
Telephone
Congress
Comments
WFH 2014 World Congress
11-15 May 2014 Melbourne
About us
FAQs
Help Line
Personal Area
Homepage
Discussion forum -
WFH 2014 World Congress
Topic -
Clotting Factor Concentrates
If you are already registered in PosterSessionOnline, enter your e-mail and click on LOGIN. Otherwise click on REGISTER
Thread / Poster
Author
Replies
Last reply
High-purity, plasma-derived, pasteurized Factor VIII concentrate in the treatment of patients with haemophilia A: update of a long-term pharmacovigilance
Robert Klamroth
1
5/2/2014 2:21:00 PM
Validation of a population pharmacokinetic model of recombinant factor VIII in boys with Haemophilia A
John Roy
1
4/23/2014 9:10:00 PM
Products registry
Mark Brooker
1
4/23/2014 8:55:00 PM
Recombinant factor IX (BAX326) in pediatric PTPs with hemophilia B: a prospective clinical trial
Miranda Chapman
1
4/23/2014 4:08:00 PM
Is switching from a pdFIX (Immunine) to a rFIX (Bax326) safe?
Borislava Pavlova
1
4/23/2014 3:58:00 PM
Safety and efficacy of a new high purity factor X concentrate in subjects with factor X deficiency undergoing surgery
Miranda Norton
1
4/23/2014 2:00:00 PM
Recombinant or plasma derived factor concentrates attitudes of patients in Germany
Christina Mondorf
1
4/22/2014 6:30:00 PM
In-vivo efficacy of human recombinant Factor IX produced by the Hepatoma cell line HuH-7
Nathalie ENJOLRAS
1
4/22/2014 1:46:00 PM
Assessment of Incremental Recovery Over Time in Postauthorization Safety Surveillance Study (PASS) of Hemophilia A Patients Switching from Moroctocog alfa or Other Factor VIII Products to Moroctocog alfa Albumin Free Cell Culture ( AF-CC)
Joan Korth-Bradley
1
4/16/2014 5:36:00 PM
Safety and efficacy of Factor VIIa-CTP, a novel long-acting coagulation factor proposing an improved prophylactic and on demand treatment of hemophilic patients in preparation for First in Human Study
Gili Hart
1
4/13/2014 1:32:00 PM
Factor VIIa-CTP, a novel long-acting coagulation factor proposing an improved prophylactic and on demand treatment of hemophilic patients, extensive invitro characterization in preparation for First in Human Study
Gili Hart
1
4/13/2014 1:29:00 PM
The role of VWF in FVIII/VWF concentrates: biochemical characterization of three different plasma-derived factor VIII products
Raimondo De Cristofaro
1
4/13/2014 7:39:00 AM
Pharmacokinetics (PK) of recombinant and plasma-derived factor IX (FIX) products in pediatric patients with severe hemophilia B
Kim Nagel
1
3/17/2014 6:18:00 PM
Successful Treatment of Glanzmanns Thrombasthenia with Recombinant Activated Factor VII NovoSeven
Bijan Keikhaei
1
3/13/2014 10:35:00 PM
In-vitro characterisation of the first therapeutic factor V concentrate
Andrew Lawrie
1
3/4/2014 2:58:00 PM
Most viewed poster for this congress
Poster:
1
Visits:
2526
Title:
A WEB SITE TO IMPROVE MANAGEMENT OF PATIENTS WITH INHERITED BLEEDING DISORDERS IN THE EMERGENCY DEPARTMENT: RESULTS AT 2 YEARS
Authors:
Annarita Tagliaferri ,
Centre:
Centro di Riferimento Regionale per la cura dellEmofilia
Poster most viewed in this topic
Poster:
1
Visits:
525
Title:
Donor Variation in the Interaction of Activated Recombinant Factor VII (rFVIIa) with Human Platelets and Detection of a High rFVIIa Binding Subpopulation
Authors:
Michael Dockal ,
Centre:
Baxter Innvoations GmbH
About us
Terms and Conditions
Special Access
Commercial Web Access
Follow us on: